Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide

Published:2012-05-05 Issue:2 Volume:134 Page:693-700
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Gjerde Jennifer,Gandini Sara,Guerrieri-Gonzaga Aliana,Haugan Moi Line L.,Aristarco Valentina,Mellgren Gunnar,DeCensi Andrea,Lien Ernst A.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.springerlink.com/index/pdf/10.1007/s10549-012-2074-9

Reference45 articles.

1. Parton M, Smith IE (2008) Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women. J Clin Oncol Off J Am Soc Clin Oncol 26:745–752. doi: 10.1200/JCO.2007.14.3016

2. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296–300. doi: 10.1016/S0140-6736(03)12342-2

3. Viale G, Regan MM, Dell’Orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, MacGrogan G, Forbes JF, Paridaens RJ, Colleoni M, Lang I, Thurlimann B, Mouridsen H, Mauriac L, Gelber RD, Price KN, Goldhirsch A, Gusterson BA, Coates AS (2011) Which patients benefit most from adjuvant aromatase inhibitors? results using a composite measure of prognostic risk in the BIG 1–98 randomized trial. Ann Oncol Off J Eur Soc Med Oncol/ESMO 22:2201–2207. doi: 10.1093/annonc/mdq738

4. Amir E, Seruga B, Niraula S, Carlsson L, Ocana A (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Nat Cancer Inst 103:1299–1309. doi: 10.1093/jnci/djr242

5. Borgna JL, Rochefort H (1980) High-affinity binding to the estrogen receptor of [3H]4-hydroxytamoxifen, an active antiestrogen metabolite. Mol Cell Endocrinol 20:71–85

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing Solid-Phase Extraction of Tamoxifen and Its Metabolites from Human Plasma Using MOF-Integrated Polyacrylonitrile Composites: A Study on CuBTC and ZIF-8 Efficacy;Nanomaterials;2023-12-26

2. Effect of Tamoxifen on Proteome Expression during In Vitro Myogenesis in Murine Skeletal Muscle C₂C₁₂ Cells;Journal of Proteome Research;2023-08-08

3. CRISISS: A Novel, Transcriptionally and Post-Translationally Inducible CRISPR/Cas9-Based Cellular Suicide Switch;International Journal of Molecular Sciences;2023-06-06

4. Cross‐Ancestry Genome‐Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations;Clinical Pharmacology & Therapeutics;2023-01-31

5. Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma;Blood Cancer Journal;2022-03-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3